HOME >> MEDICINE >> NEWS
Oral formulation of antipsychotic offers 'user-friendly' alternative to injections for patients with acute psychosis

[11 September 2000, Munich] -- Although many physicians rely on intramuscular injections of antipsychotic drugs to treat patients who need emergency treatment for psychotic agitation, new research has found that the oral-solution form of Risperdal™ (risperidone) is just as effective and may be a more acceptable alternative for both caregivers and patients(1).

The study, which was presented today at a major international neuropsychopharmacology congress in Munich, found that Risperdal works as quickly and is as effective in reducing symptoms of psychotic agitation as an intramuscular (IM) injection of haloperidol, an older, conventional antipsychotic. Both medications were administered in combination with the antianxiety drug lorazepam.

"When there are two drugs that are equally efficacious, a physician's next consideration when selecting an antipsychotic drug in emergency situations should be patient choice and compliance," said Dr Glenn Currier, lead investigator and assistant professor of the departments of psychiatry and emergency medicine at the University of Rochester. "When patients experiencing psychotic agitation -- usually due to schizophrenia -- end up in the emergency room, they often are confused, scared and paranoid. Injections are painful, and can be perceived as hostile and 'coercive.' This can be a significant barrier to the physician's ability to deliver good care, and to the patient's ability to accept it."

In contrast, an oral solution (liquid) is more easily administered in emergency situations than pills, and is non-invasive. Patients also can continue on the same medication when they leave the hospital, which encourages long-term compliance. Dr. Currier adds that an oral-solution formulation offers benefits to caregivers as well. Injections expose staff members at hospitals and other facilities to an increased risk of needlepricks and a resultant exposure to diseases such as AIDS and hepatitis -- especially w
'"/>

Contact: John Gisborne
john.gisborne@ketchumcomms.co.uk
44-207-465-8753
Ketchum
10-Sep-2000


Page: 1 2 3

Related medicine news :

1. Newer formulation of heparin improves outcomes for suspected heart attack patients
2. Newer vitamin D formulation appears to help dialysis patients live longer
3. Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine)
4. Researchers warn antipsychotic drug
5. New antipsychotic drugs combined with nicotine patch help schizophrenics quit smoking
6. New study shows prescribing of newer antipsychotic medication risperdal may save millions in schizophrenia care
7. UCSF study offers insight into human circadian rhythms
8. Research offers hope of new treatments for liver damage
9. Portable system offers dialysis patients liberating changes
10. New laparoscopic hysterectomy offers quicker recovery time than traditional surgery
11. UIC offers new weight loss surgery for obese teens

Post Your Comments:
(Date:9/2/2015)... ... , ... Every year at this time, students prepare to go back to ... face the academic workload confronting them. They just don’t have the skills needed to ... teach students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces Hand Free Pocket Cop, a safety invention that protects people from crime ... worth $31 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:9/2/2015)... ... , ... Ovarian cancer continues to be the deadliest of all gynecologic cancers. ... her lifetime is approximately 1 in 75. This year it is estimated that approximately ... , There is no test to detect ovarian cancer. A Pap test does ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... the pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream ... cream combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense ...
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a North Carolina ... Inc. 5000 List, an independent ranking of the fastest- growing private companies ... this achievement puts Canopy in rarefied company. Over the years, this elite group ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2
(Date:9/2/2015)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and ... into a definitive agreement under which Valeant will acquire ... SURG ) for $6.50 per share in cash. In ... receive additional cash payments of up to $1.00 per ... closing.  The transaction is expected to close in the ...
(Date:9/2/2015)... 2015 Tumultuous market conditions – including changes ... M&A activity – have led more than half of ... sales reps. This marks the first time that the ... halfway point, according to the spring 2015 AccessMonitor™ ... ZS . AccessMonitor™ aggregates sales-call ...
(Date:9/2/2015)... JUNCTION, N.J. , Sept. 2, 2015 ... immunotherapy leader commercializing its CytoSorb ® blood purification ... around the world, announced that CEO Dr. Phillip ... & Renshaw Annual Global Investment Conference (sponsored by ... 8-10 th in New York City.  ...
Breaking Medicine Technology:Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4
Cached News: